{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Weight Reversal Post Tirzepatide Withdrawal","description":" In this week\u2019s View, Dr. Eagle\u202flooks\u202fat the&amp;nbsp;DANISH&amp;nbsp;trial extended&amp;nbsp;follow-up, evaluating which patients&amp;nbsp;benefit&amp;nbsp;most from primary prevention&amp;nbsp;implantable&amp;nbsp;cardioverter&amp;nbsp;defibrillator&amp;nbsp;(ICD) implantation.\u202fHe then\u202fexplores\u202fthe&amp;nbsp;SURMOUNT-4 study on weight reversal post&amp;nbsp;tirzepatide&amp;nbsp;withdrawal.&amp;nbsp;Finally,\u202fDr. Eagle examines&amp;nbsp;two JACC&amp;nbsp;articles&amp;nbsp;that&amp;nbsp;cover&amp;nbsp;disease&amp;nbsp;monitoring: one tracking&amp;nbsp;the progression of&amp;nbsp;transthyretin amyloid cardiomyopathy (ATTR-CM)&amp;nbsp;and another&amp;nbsp;assessing&amp;nbsp;cardiovascular&amp;nbsp;risks in patients receiving cancer therapy.\u202f\u202f&amp;nbsp;   &amp;nbsp;Subscribe to Eagle\u2019s Eye View&amp;nbsp;&amp;nbsp;  ","author_name":"Eagle's Eye View: Your Weekly CV Update From ACC.org","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39416980\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/196587455"}